Compare TCBK & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBK | TSHA |
|---|---|---|
| Founded | 1975 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1995 | 2020 |
| Metric | TCBK | TSHA |
|---|---|---|
| Price | $58.20 | $5.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $54.60 | $11.63 |
| AVG Volume (30 Days) | 579.3K | ★ 2.9M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 6.94 | 5.56 |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $53,445,000.00 | $9,773,000.00 |
| Revenue This Year | $12.03 | N/A |
| Revenue Next Year | $4.47 | $1,152.42 |
| P/E Ratio | $55.81 | ★ N/A |
| Revenue Growth | 4.12 | ★ 17.28 |
| 52 Week Low | $39.84 | $2.54 |
| 52 Week High | $61.71 | $7.30 |
| Indicator | TCBK | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 44.20 |
| Support Level | $48.57 | $5.28 |
| Resistance Level | $61.71 | $6.01 |
| Average True Range (ATR) | 1.39 | 0.47 |
| MACD | -0.28 | -0.06 |
| Stochastic Oscillator | 57.33 | 26.18 |
TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.